文献速递痛风与晶体性关节病

痛风药物注册临床试验的参与者能否代表一般人群中的痛风患者

Are participants in gout medication registration clinical trials representative of people with gout in the general population?
PubMed 文献 · Semin Arthritis Rheum · 2025-01-29

本研究分析2009至2023年美国食品药品监督管理局(FDA)批准的痛风药物3期临床试验,比较其参与者人口学特征和合并症与2007-2008及2015-2016年美国国家健康与营养调查(NHANES)痛风人群数据。结果显示,试验过度代表男性、年轻人和白人,而高血压、既往心肌梗死、肾结石和糖尿病患者比例偏低,BMI≥30 kg/m2者比例偏高。作者认为这些试验未纳入能代表美国一般痛风人群的研究人群。

要点

  • 2009至2023年FDA批准的痛风药物3期试验过度代表男性、年轻人和白人参与者。
  • 试验参与者中高血压、既往心肌梗死、肾结石和糖尿病患者比例偏低,BMI≥30 kg/m2者比例偏高。
  • 作者建议未来3期试验应确保更多纳入女性、老年人、不同族裔及常见痛风相关合并症患者。

核心结论

  • 自2009年以来FDA批准的痛风药物试验未纳入能代表美国一般痛风人群的研究人群,尤其在年龄、族裔和心血管代谢合并症方面。

研究设计与样本

  • 通过检索FDA和CenterWatch网站确定痛风治疗药物,分析2009至2023年FDA批准的痛风药物3期临床试验数据。
  • 提取人口学变量(性别、年龄、族裔)和合并症(高血压、心肌梗死、心力衰竭、肾结石、慢性肾病、BMI≥30 kg/m2和糖尿病),与2007-2008及2015-2016年NHANES已发表数据比较。
  • 数据采用随机效应模型合并,以百分比和95%置信区间(CI)呈现。

主要发现

  • 共纳入12项3期临床试验,涵盖非布司他、秋水仙碱、培戈洛酶、lesinurad和卡那奴单抗。
  • 与NHANES痛风人群相比,临床试验过度代表男性、年轻人和白人参与者。
  • 临床试验参与者中高血压、既往心肌梗死、肾结石和糖尿病患者比例偏低,而BMI≥30 kg/m2者比例偏高。

临床怎么用

  • 原文未据此给出推荐,作者在结论中建议未来3期试验应确保更多纳入女性、老年人、不同族裔及常见痛风相关合并症患者,以扩大适用性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ensuring clinical trial participants are representative of the target population is important for the generalizability of trial findings. This study aimed to determine if phase 3 clinical trials of gout medications approved by the US Food and Drug Administration (FDA) included participants representative of the US general population with gout. METHODS: Gout therapeutics were identified by searching the FDA and CenterWatch websites. Data from phase 3 clinical trials of FDA approved gout medications between 2009 and 2023 were analyzed. Demographic variables (sex, age, and ethnicity) and comorbidities (hypertension, myocardial infarction, heart failure, nephrolithiasis, chronic kidney disease, BMI ≥30 kg/m2, and diabetes) were extracted and compared with published data from the 2007-2008 and 2015-2016 US National Health and Nutrition Examination Survey (NHANES). Data were pooled using a random effects model and presented as a percentage with a 95 % confidence interval. RESULTS: Twelve phase 3 clinical trials were included, covering febuxostat, colchicine, pegloticase, lesinurad, and canakinumab. Compared to the NHANES gout population, clinical trials over-represented men, younger individuals, and White ethnicity participants. Under-representation was observed for clinical trial participants with hypertension, prior myocardial infarction, nephrolithiasis, and diabetes, while those with a BMI ≥30 kg/m2 were over-represented. CONCLUSIONS: FDA approved gout medication trials since 2009 have not enrolled a study population that is representative of the US general population with gout, particularly regarding age, ethnicity, and cardiometabolic comorbidities. For broader applicability, future phase 3 trials should ensure the greater inclusion of women, older individuals, diverse ethnicities, and those with common gout-associated comorbid conditions.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Liu J, Gamble GD, Dalbeth N, et al. Are participants in gout medication registration clinical trials representative of people with gout in the general population? Semin Arthritis Rheum. 2025. PMID: 39919487. doi:10.1016/j.semarthrit.2025.152647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。